Isovue-M 200 with Computed Tomography Fluoroscopy Guidance in Imaging Patients with Urological Cancer Metastatic to Bone, Lymph Node, Soft Tissue, or Liver

Inclusion Criteria

• Histologically confirmed diagnosis of adenocarcinoma of the prostate, renal cell carcinoma, or urothelial carcinoma; small cell or neuroendocrine tumors of the prostate are also permitted
• Radiographic evidence of at least one bone, lymph node, soft tissue or liver metastasis, that is amenable to iodinated contrast injection, as judged by the study radiologist
• Platelets >= 100,000
• International normalized ratio (INR) =< 1.3
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

• History of intercurrent or past medical or psychiatric illness that would make participation in a research biopsy protocol difficult or not feasible at the discretion of the principal investigator or co-investigator(s)
• Creatinine (Cr) > 2.0
• History of iodinated contrast allergy
• For patients undergoing a research only biopsy: requirement for anticoagulation with heparin, low molecular weight heparin, clopidogrel, rivaroxaban, dabigatran, apixaban, warfarin, aggrenox, fondaparux, ticagrelor, etc (aspirin and other nonsteroidal antiinflammatory drugs [NSAIDs] are ok but should be held prior to biopsy in accordance with institutional standard of care)
• Any other contraindication to CT with iodinated contrast, as CT with contrast will be used in the study